Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof
AssigneeYeda Research and Development Co. Ltd.
InventorsIrit SAGI, Vishnu MOHAN
Life of this patent
Estimating the term…
Abstract
An antibody comprising an antigen recognition region which binds a catalytic site of MMP-7, having complementarity determining region (CDR) amino acid sequences as set forth in: SEQ ID NOs: 3 (CDR1), 4 (CDR2) and 5 (CDR3), sequentially arranged from N to C on a light chain of the antibody; and SEQ ID NOs: 6 (CDR1), 7 (CDR2) and 8 (CDR3), sequentially arranged from N to C on a heavy chain of the antibody.
Claims23
1-4. (canceled)
A method of treating a disease associated with imbalanced or abnormal activity of MMP-7 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antibody which comprises an antigen recognition region which binds a catalytic site of MMP-7, having complementarity determining region (CDR) amino acid sequences as set forth in:
- SEQ ID NOs:
- 3 (CDR1), 4 (CDR2) and 5 (CDR3), sequentially arranged from N to C on a light chain of the antibody;
- and SEQ ID NOs:
- 6 (CDR1), 7 (CDR2) and 8 (CDR3), sequentially arranged from N to C on a heavy chain of the antibody, thereby treating the disease associate with imbalanced or abnormal activity of MMP-7 in the subject.
8-10. (canceled)
A method of treating cancer in a subject in need thereof comprising:
- (a) analyzing in a sample of the subject for an amount of MMP-7;
- and
- (b) administering to the subject a therapeutically effective amount of the antibody which comprises an antigen recognition region which binds a catalytic site of MMP-7, having complementarity determining region (CDR) amino acid sequences as set forth in:
- SEQ ID NOs:
- 3 (CDR1), 4 (CDR2) and 5 (CDR3), sequentially arranged from N to C on a light chain of the antibody;
- and SEQ ID NOs:
- 6 (CDR1), 7 (CDR2) and 8 (CDR3), sequentially arranged from N to C on a heavy chain of the antibody upon confirmation that said amount of said MMP-7 is above a predetermined level, thereby treating the cancer.
A method of treating cancer in a subject in need thereof comprising:
- (a) analyzing in a sample of the subject for an amount of MMP-7 using an antibody which comprises an antigen recognition region which binds a catalytic site of MMP-7, having complementarity determining region (CDR) amino acid sequences as set forth in:
- SEQ ID NOs:
- 3 (CDR1), 4 (CDR2) and 5 (CDR3), sequentially arranged from N to C on a light chain of the antibody;
- and SEQ ID NOs:
- 6 (CDR1), 7 (CDR2) and 8 (CDR3), sequentially arranged from N to C on a heavy chain of the antibody;
- and
- (b) administering to the subject a therapeutically effective amount of an agent which down-regulates the amount of said MMP-7 upon confirmation that said amount of said MMP-7 is above a predetermined level, thereby treating the cancer.
(canceled)
A method of treating pancreatic cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antibody comprising an antigen recognition region which binds a catalytic site of MMP-7, wherein the antibody inhibits the activity of said MMP-7 and wherein the Ki of the antibody towards said MMP-7 is at least 5 times lower than a Ki of the antibody towards MMP2 or MMP9, thereby treating the pancreatic cancer.
(canceled)
An article of manufacture comprising an antibody which comprises an antigen recognition region which binds a catalytic site of MMP-7, having complementarity determining region (CDR) amino acid sequences as set forth in:
- SEQ ID NOs:
- 3 (CDR1), 4 (CDR2) and 5 (CDR3), sequentially arranged from N to C on a light chain of the antibody;
- and SEQ ID NOs:
- 6 (CDR1), 7 (CDR2) and 8 (CDR3), sequentially arranged from N to C on a heavy chain of the antibody and a chemotherapeutic agent.
28-35. (canceled)
Dependencies are inferred from the claim text.